Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Zomedica (ZOMDF – Research Report) today and set a price target of $0.25. The company’s shares opened today at $0.03.
ANN ARBOR, MI / ACCESS Newswire / February 12, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback